PortViewPortView
OraSure Technologies logo

OraSure Technologies (OSUR) Stock Analysis

NASDAQHealthcareMedical - Instruments & Supplies

$3.68+4.11%
1-year price historyRange $2.11 – $4.50
52-week range$3.68
$2.08$4.58

What OraSure Technologies does

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Key metrics

Market cap
$253.02M
P/E (TTM)
-5.33
EPS (TTM)
$-0.69
Beta
1.01
Dividend yield
0.00%
Revenue / share
$1.63
50-day avg
$4.03
200-day avg
$3.24
52-week high
$4.58
52-week low
$2.08
CEO
Carrie Eglinton Manner

ETFs linked to OSUR

Broad-market and Healthcare sector ETFs an investor holding OraSure Technologies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how OSUR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze OSUR in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for OraSure Technologies?
OraSure Technologies trades under the ticker OSUR on NASDAQ.
Which exchange is OSUR listed on?
OSUR is listed on NASDAQ.
What sector does OraSure Technologies operate in?
OraSure Technologies is classified in the Healthcare sector (Medical - Instruments & Supplies industry).
How can PortView help analyze OSUR in a portfolio?
PortView shows OSUR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.